Source: Benzinga

Guide: Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million ...Full story available on Benzinga.com

Read full article »

Guide's Competitors | Guide's News | Guide's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

1-25

Co-Founder

Cory Sago

CEO Approval Rating

90/100

Guide Therapeutics is a Georgia-based biopharmaceutical company that develops and commercializes gene therapies for the treatment of serious diseases.